ArticleFrontiers in medicine2025
Case Report: A severe drug-induced immune hemolytic anemia caused by vancomycin.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Vancomycin-induced immune hemolytic anemia: a case report and literature review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced immune hemolytic anemia (DIIHA) is an adverse effect of some therapeutics, which is potentially life-threatening. A high priority is required in clinical treatment, since the number of medications known to induce DIIHA continues to expand. This study reports on a case of vancomycin-induced hemolysis observed in a patient in China. Case description: A 50-year-old man with negative irregular antibody detection tests developed hemolytic anemia on the eighth day after replacement and repair surgery of his left knee. The patient was treated with vancomycin-mixed bone cement during the surgery, as well as vancomycin intravenously in the postoperative period every day. On the eighth day after surgery, he developed a rapid decline in hemoglobin level, elevation of indirect bilirubin and lactate dehydrogenase levels in serum, and presence of hemoglobin in urine. Laboratory analysis revealed high-titer antibodies against vancomycin in the patient's serum, which were mainly immunoglobulin G (IgG) antibodies, and demonstrated greater specificity for the blood group N antigen. Conclusion: This case, together with previous reports, underscores the importance of considering DIIHA in patients who exhibit unexplained decreases in hemoglobin levels following a new medication, especially antibiotics. A thorough examination of the patient's medical history and the identification of specific drug-dependent antibodies through serological tests can provide crucial insights for diagnosing DIIHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.